Patents by Inventor Richard Yau

Richard Yau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trispecific T cell Engagers
    Publication number: 20240425611
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: June 28, 2024
    Publication date: December 26, 2024
    Inventors: Margaret KAROW, Richard Yau, Jackie SHENG
  • Bispecific T cell Engagers
    Publication number: 20240343827
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: March 21, 2024
    Publication date: October 17, 2024
    Inventors: Margaret KAROW, Richard Yau, Jackie SHENG
  • Trispecific T cell engagers
    Patent number: 12060434
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: August 13, 2024
    Assignee: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Bispecific T cell engagers
    Patent number: 11976133
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: May 7, 2024
    Assignee: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Trispecific T cell Engagers
    Publication number: 20210269551
    Abstract: Provided are trispecific T Cell Engagers or TSMAb's, antibodies that can simultaneously engage three different types of epitopes on the same target or on different targets. More specifically, the invention is directed to trispecific molecules that bind to DLL3, MUC17 or CLDN18.2 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 2, 2021
    Applicant: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng
  • Bispecific T cell Engagers
    Publication number: 20210246222
    Abstract: Provided are bispecific T Cell Engagers. More specifically, the invention is directed to bispecific molecules that bind to DLL3, MUC17 or CLD18 and activate CD (cluster of differentiation) molecules (e.g. CD3, CD28 and CD137). Also provided are methods of treating an ailment such as cancer using an antibody (or fragment) against DLL3, MUC17 or CLD18 paired with an antibody (or fragment) of an agonist antibody that activates CD3, CD28 and/or CD137.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 12, 2021
    Applicant: Gensun Biopharma Inc.
    Inventors: Margaret Karow, Richard Yau, Jackie Sheng